An approved gene therapy restores vision in children born with a rare form of blindness. There are other gene therapies advancing through clinical trials that could one day treat — and potentially cure — people suffering from devastating diseases like sickle cell, hemophilia, and Duchenne muscular dystrophy, among others.
Overactive bladder is bothersome, but it is most definitely not a devastating disease. Yet Tuesday, the biotech firm Urovant Sciences announced plans to pursue clinical development of a gene therapy to treat people who have this troubling but by no means life-threatening condition.
Unlock this article by subscribing to STAT Plus and enjoy your first 30 days free!
GET STARTEDWhat is it?
STAT Plus is STAT's premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis. Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond.
What's included?
- Daily reporting and analysis
- The most comprehensive industry coverage from a powerhouse team of reporters
- Subscriber-only newsletters
- Daily newsletters to brief you on the most important industry news of the day
- Online intelligence briefings
- Frequent opportunities to engage with veteran beat reporters and industry experts
- Exclusive industry events
- Premium access to subscriber-only networking events around the country
- The best reporters in the industry
- The most trusted and well-connected newsroom in the health care industry
- And much more
- Exclusive interviews with industry leaders, profiles, and premium tools, like our CRISPR Trackr.
About the Author
Overactive bladder is not a serious problem, then until Feuerstein experiences it.